Publicacións (124) Publicacións de Ignacio Gil Bazo

2024

  1. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

    Molecular Cancer, Vol. 23, Núm. 1

2023

  1. A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

    Frontiers in Immunology, Vol. 14

  2. Biología celular del cáncer

    Biología celular biomédica (Elsevier), pp. 375-407

  3. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

  4. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS -Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study

    Journal of Clinical Oncology, Vol. 41, Núm. 14, pp. 2651-2660

  5. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

    Journal of Translational Medicine, Vol. 21, Núm. 1

  6. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

  7. Tratamiento actual del cáncer de pulmón de células no pequeñas con mutación de EGFR: primera línea y manejo a la progression

    Revisiones en Cancer, Vol. 37, Núm. 4, pp. 169-179

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  2. Impact on the Nutritional Status and Inflammation of Patients with Cancer Hospitalized after the SARS-CoV-2 Lockdown

    Nutrients, Vol. 14, Núm. 13

  3. MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

    European Journal of Cancer, Vol. 174, pp. S122

  4. The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations

    JCO global oncology, Vol. 8, pp. e2200123

2021

  1. Delta-radiomics signature for prediction of survival in advanced nsclc patients treated with immunotherapy

    Proceedings - International Symposium on Biomedical Imaging

2020

  1. Are Immune Checkpoint Inhibitors Effective Against Uncommon Oncogene-Driven NSCLC Subtypes?

    Journal of Thoracic Oncology

  2. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)

    Critical Reviews in Oncology/Hematology, Vol. 151

  3. Corrigendum to “Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)” [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978] (Critical Reviews in Oncology / Hematology (2020) 151, (S1040842820301165), (10.1016/j.critrevonc.2020.102978))

    Critical Reviews in Oncology/Hematology

  4. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

    Annals of Oncology, Vol. 31, Núm. 2, pp. 274-282

  5. Id1 and pd-1 combined blockade impairs tumor growth and survival of KRAS-mutant lung cancer by stimulating PD-l1 expression and tumor infiltrating CD8+ T cells

    Cancers, Vol. 12, Núm. 11, pp. 1-22

  6. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC

    Critical Reviews in Oncology/Hematology, Vol. 148

  7. Oncogenes in cancer: Using the problem as part of the solution

    Cancers